We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

BD Sells Surgical Instrumentation Platform to STERIS

By HospiMedica International staff writers
Posted on 21 Jun 2023

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has signed a definitive agreement to sell its Surgical Instrumentation platform to STERIS (Mentor, OH, USA) for USD 540 million. The divestiture includes the transfer of V. Mueller, Snowden-Pencer, and Genesis branded products as well as three manufacturing facilities.

STERIS is a global provider of products and services that support patient care, particularly in the field of infection prevention. It offers a wide range of infection prevention products and other procedural services, mainly aimed at healthcare, pharmaceutical, medical device, and dental clients. The acquisition of BD's surgical instrumentation platform, which complements STERIS's Healthcare segment, will empower STERIS to more effectively meet the product and service demands of hospitals and surgery centers. The platform has three dedicated manufacturing sites and about 20,000 SKUs in its portfolio. The divestment of its Surgical Instrumentation platform aligns with the "Simplify" objective of BD's 2025 strategy and represents a significant move towards streamlining its product portfolio and manufacturing network.


Image: The divestiture of the surgical instrumentation platform includes V. Mueller, Snowden-Pencer and Genesis branded products (Photo courtesy of BD)
Image: The divestiture of the surgical instrumentation platform includes V. Mueller, Snowden-Pencer and Genesis branded products (Photo courtesy of BD)

"The Surgical Instrumentation platform has a 120-year legacy of providing reliable and trusted high-quality products, and STERIS is well positioned to maximize the value of this extensive portfolio and is fortunate to be adding such a dedicated and talented team to its organization," said Rick Byrd, president of the Interventional segment at BD. "This transaction further advances the BD Interventional segment's focus on high-growth end markets. We look forward to continuing to address unmet needs in health care through a highly differentiated and innovative set of solutions and products."

Related Links:
Becton, Dickinson and Company 
STERIS 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Single-Use Instrumentation
FASTPAK
New
Resting Electrocardiograph
ECG Top D/BT

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024